Conferences

New research shows fezolinetant significantly reduces the frequency and severity of hot flashes in Hispanic women, offering a safer alternative to hormone replacement therapy.

A new study highlights gestational hypertension as a significant predictor of cardiovascular disease in menopausal women, challenging previous assumptions about preeclampsia’s role.

PH80 nasal spray shows promise in reducing menopausal hot flashes, offering an effective and safe non-hormonal treatment option.

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.

Low rates of hormone therapy use have been reported among midlife women, stagnating after decreases in the immediate aftermath of the Women’s Health Initiative.

A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.